Last reviewed · How we verify
NCT06363708
Tislelizumab in Combination With Chemotherapy as a Neoadjuvant Treatment for Advanced Endometrial Cancer
NA trial testing Tislelizumab in Endometrial Neoplasms in 20 participants. Not yet recruiting.
1 December 2025
Quick facts
| Lead sponsor | Zhongnan Hospital |
|---|---|
| Phase | NA |
| Status | Not yet recruiting |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 20 |
| Start date | 1 June 2024 |
| Primary completion | 1 December 2025 |
| Estimated completion | 30 June 2026 |
| Sites | 3 locations across China |
Drugs / interventions tested
- Tislelizumab (TISLELIZUMAB) — full drug profile →
- Paclitaxel — full drug profile →
- Carboplatin (Carboplatin) — full drug profile →
Conditions studied
- Endometrial Neoplasms — all drugs for Endometrial Neoplasms →
Sponsor
Zhongnan Hospital
Who can join
18 and older, female only, with Endometrial Neoplasms. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The goal of this clinical trial is to evaluate the efficacy and safety of tislelizumab in combination with chemotherapy as a neoadjuvant treatment for advanced endometrial cancer.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06363708
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Tislelizumab
Trials testing the same drug.
- NCT07469306 — Short-Course RT Plus CAPOX and Tislelizumab vs Long-Course CRT Plus Tislelizumab for Locally Advanced Rectal Cancer · Phase 2 · not yet recruiting
- NCT07475026 — A Study of Neoadjuvant Tislelizumab Plus Lenvatinib in Resectable HCC at High Risk of Recurrence · Phase 3 · not yet recruiting
- NCT07528274 — Microwave Ablation Plus Tislelizumab and Docetaxel in Advanced NSCLC After First-Line Immunotherapy Failure · Phase 2 · recruiting
- NCT07290985 — AACR Adaptive Biomarker-Driven Organ Preservation Trial in Gastroesophageal Adenocarcinomas · Phase 2 · not yet recruiting
- NCT07518706 — Neoadjuvant Tislelizumab-Lenvatinib vs Surgery Alone in Stage Ia HCC With Narrow Margin · Phase 2 · not yet recruiting
Other recruiting trials for Endometrial Neoplasms
Currently open trials in the same condition.
- NCT07114653 — The Role of POLE Mutation in High Risk Endometrial Cancer. · recruiting
- NCT07040657 — Comparison of Two-Position and Four-Position Cervical Injection Techniques for Sentinel Lymph Node Mapping in Endometria · NA · recruiting
- NCT06714617 — Evaluate BL-M17D1 in Patients w/HER2-Expressing/Mutant Advanced or Metastatic Solid Tumors · Phase 1 · active not recruiting
- NCT06751329 — A Study of DM002 in Patients With Advanced Solid Tumors · Phase 1 · recruiting
- NCT06023862 — A Three-arm Randomized Phase II Study of Dostarlimab Alone or With Bevacizumab Versus Nonplatinum Chemotherapy in Recurr · Phase 2 · recruiting
Other Zhongnan Hospital trials
Trials by the same sponsor.
- NCT07515963 — FULIRI Plus Targeted Therapy for First-line Conversion Therapy of Colorectal Cancer Liver Metastases. · Phase 2 · not yet recruiting
- NCT07420036 — An Open-label, Single-arm, Single-center Study to Evaluate the Diagnostic Efficacy of a Novel PET Probe, 68Ga-SFB6-ZN01, · EARLY_PHASE1 · not yet recruiting
- NCT07453966 — Efficacy and Safety of Intrapulmonary Percussive Ventilation in Patients With Pulmonary Infection Receiving Invasive Mec · NA · recruiting
- NCT07363330 — A Phase II Study of Utidelone With Toripalimab in Advanced Cervical Cancer · Phase 2 · not yet recruiting
- NCT07460258 — A Study on the Effect of Medical Students' Literature Reading Patterns on Cognitive Load and Academic Writing Ability · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06363708 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Zhongnan Hospital
- Last refreshed: 12 April 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06363708.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing